Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890230299> ?p ?o ?g. }
- W2890230299 endingPage "8510" @default.
- W2890230299 startingPage "8510" @default.
- W2890230299 abstract "8510 Background: The feasibility of combined chemo-radiotherapy (chemo-RT) and concurrent PD-1 inhibition is of high scientific interest and has shown promising results in pre-clinical models. So far, concurrent immune-checkpoint inhibition and radical thoracic RT has never been assessed in a clinical trial. Methods: NICOLAS is a phase II trial evaluating the safety of the addition of nivolumab to first-line chemo-RT in stage III NSCLC. Efficacy will be evaluated if a safety conclusion has been achieved, based on a hierarchical design. Patients received 3 cycles of platinum-based chemotherapy (etoposide, vinorelbine or pemetrexed) and radical RT of 66 Gy. Nivolumab treatment (240 mg / Q4W) started concurrently to RT. The primary safety endpoint is defined as the rate of pneumonitis grade ≥3 at 6 months post RT. An interim analysis was scheduled when the first 21 patients reached 3 months follow-up after completion of RT, based on the assumption that 70% of the pneumonitis events occur within the first 3 months. An early positive safety conclusion is reached at interim analysis if there is no incidence of pneumonitis grade ≥3 in the initial 21 patients (exact group sequential design at one-sided significance level of 0.05 and power = 83%, testing a 6-month pneumonitis rate ≥33% versus ≤15%). Results: Up to December 14, 2017, 49 patients have been recruited with a median follow-up of 6.6 months [95% CI: 5.6, 7.8]. The median age is 63 years, with the majority of the patients being male (67.3%), former smokers (75.5%) and with tumor stage IIIb (65.3%). The most frequently observed adverse events (AEs) are fatigue and anemia. No unexpected AEs or increased safety risk were observed. For the first 21 patients, no pneumonitis grade ≥3 was observed by the end of the 3-month post RT follow-up period. The majority of these patients (18 patients) were on a concurrent chemo-RT schedule. Conclusions: This early interim safety analysis provides evidence that the addition of nivolumab to concurrent chemo-RT is safe and tolerable. In a next step, the 1-year progression-free survival will be evaluated according to the hierarchical design in an expanded patient cohort. Clinical trial information: NCT02434081." @default.
- W2890230299 created "2018-09-27" @default.
- W2890230299 creator A5003670561 @default.
- W2890230299 creator A5012411744 @default.
- W2890230299 creator A5019129337 @default.
- W2890230299 creator A5021704329 @default.
- W2890230299 creator A5023510680 @default.
- W2890230299 creator A5027562389 @default.
- W2890230299 creator A5038323479 @default.
- W2890230299 creator A5052958356 @default.
- W2890230299 creator A5055289994 @default.
- W2890230299 creator A5055480892 @default.
- W2890230299 creator A5063300526 @default.
- W2890230299 creator A5066966754 @default.
- W2890230299 creator A5074816848 @default.
- W2890230299 creator A5075607330 @default.
- W2890230299 creator A5078159755 @default.
- W2890230299 creator A5084481574 @default.
- W2890230299 creator A5085427488 @default.
- W2890230299 creator A5086508202 @default.
- W2890230299 creator A5090324173 @default.
- W2890230299 date "2018-05-20" @default.
- W2890230299 modified "2023-09-26" @default.
- W2890230299 title "Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial." @default.
- W2890230299 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.8510" @default.
- W2890230299 hasPublicationYear "2018" @default.
- W2890230299 type Work @default.
- W2890230299 sameAs 2890230299 @default.
- W2890230299 citedByCount "19" @default.
- W2890230299 countsByYear W28902302992019 @default.
- W2890230299 countsByYear W28902302992020 @default.
- W2890230299 countsByYear W28902302992022 @default.
- W2890230299 countsByYear W28902302992023 @default.
- W2890230299 crossrefType "journal-article" @default.
- W2890230299 hasAuthorship W2890230299A5003670561 @default.
- W2890230299 hasAuthorship W2890230299A5012411744 @default.
- W2890230299 hasAuthorship W2890230299A5019129337 @default.
- W2890230299 hasAuthorship W2890230299A5021704329 @default.
- W2890230299 hasAuthorship W2890230299A5023510680 @default.
- W2890230299 hasAuthorship W2890230299A5027562389 @default.
- W2890230299 hasAuthorship W2890230299A5038323479 @default.
- W2890230299 hasAuthorship W2890230299A5052958356 @default.
- W2890230299 hasAuthorship W2890230299A5055289994 @default.
- W2890230299 hasAuthorship W2890230299A5055480892 @default.
- W2890230299 hasAuthorship W2890230299A5063300526 @default.
- W2890230299 hasAuthorship W2890230299A5066966754 @default.
- W2890230299 hasAuthorship W2890230299A5074816848 @default.
- W2890230299 hasAuthorship W2890230299A5075607330 @default.
- W2890230299 hasAuthorship W2890230299A5078159755 @default.
- W2890230299 hasAuthorship W2890230299A5084481574 @default.
- W2890230299 hasAuthorship W2890230299A5085427488 @default.
- W2890230299 hasAuthorship W2890230299A5086508202 @default.
- W2890230299 hasAuthorship W2890230299A5090324173 @default.
- W2890230299 hasConcept C121608353 @default.
- W2890230299 hasConcept C126322002 @default.
- W2890230299 hasConcept C141071460 @default.
- W2890230299 hasConcept C143998085 @default.
- W2890230299 hasConcept C203092338 @default.
- W2890230299 hasConcept C2776694085 @default.
- W2890230299 hasConcept C2777701055 @default.
- W2890230299 hasConcept C2777714996 @default.
- W2890230299 hasConcept C2778239845 @default.
- W2890230299 hasConcept C2779384505 @default.
- W2890230299 hasConcept C2779524853 @default.
- W2890230299 hasConcept C2780030458 @default.
- W2890230299 hasConcept C2780350996 @default.
- W2890230299 hasConcept C2781413609 @default.
- W2890230299 hasConcept C509974204 @default.
- W2890230299 hasConcept C535046627 @default.
- W2890230299 hasConcept C61943457 @default.
- W2890230299 hasConcept C71924100 @default.
- W2890230299 hasConceptScore W2890230299C121608353 @default.
- W2890230299 hasConceptScore W2890230299C126322002 @default.
- W2890230299 hasConceptScore W2890230299C141071460 @default.
- W2890230299 hasConceptScore W2890230299C143998085 @default.
- W2890230299 hasConceptScore W2890230299C203092338 @default.
- W2890230299 hasConceptScore W2890230299C2776694085 @default.
- W2890230299 hasConceptScore W2890230299C2777701055 @default.
- W2890230299 hasConceptScore W2890230299C2777714996 @default.
- W2890230299 hasConceptScore W2890230299C2778239845 @default.
- W2890230299 hasConceptScore W2890230299C2779384505 @default.
- W2890230299 hasConceptScore W2890230299C2779524853 @default.
- W2890230299 hasConceptScore W2890230299C2780030458 @default.
- W2890230299 hasConceptScore W2890230299C2780350996 @default.
- W2890230299 hasConceptScore W2890230299C2781413609 @default.
- W2890230299 hasConceptScore W2890230299C509974204 @default.
- W2890230299 hasConceptScore W2890230299C535046627 @default.
- W2890230299 hasConceptScore W2890230299C61943457 @default.
- W2890230299 hasConceptScore W2890230299C71924100 @default.
- W2890230299 hasIssue "15_suppl" @default.
- W2890230299 hasLocation W28902302991 @default.
- W2890230299 hasOpenAccess W2890230299 @default.
- W2890230299 hasPrimaryLocation W28902302991 @default.
- W2890230299 hasRelatedWork W1989003092 @default.
- W2890230299 hasRelatedWork W2053130000 @default.
- W2890230299 hasRelatedWork W2137737798 @default.
- W2890230299 hasRelatedWork W2351131972 @default.
- W2890230299 hasRelatedWork W2351388913 @default.